AR068045A1 - Derivados de catecolamina y prodrogas de los mismos - Google Patents
Derivados de catecolamina y prodrogas de los mismosInfo
- Publication number
- AR068045A1 AR068045A1 ARP080103714A ARP080103714A AR068045A1 AR 068045 A1 AR068045 A1 AR 068045A1 AR P080103714 A ARP080103714 A AR P080103714A AR P080103714 A ARP080103714 A AR P080103714A AR 068045 A1 AR068045 A1 AR 068045A1
- Authority
- AR
- Argentina
- Prior art keywords
- octahydro
- quinolin
- racemic
- benzo
- diol
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- IFMZKCMCMMMEKQ-UHFFFAOYSA-N quinoline-6,7-diol Chemical compound C1=CN=C2C=C(O)C(O)=CC2=C1 IFMZKCMCMMMEKQ-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- -1 phenylacetyl Chemical group 0.000 abstract 2
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 abstract 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 150000003943 catecholamines Chemical class 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/08—Aza-anthracenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Portable Nailing Machines And Staplers (AREA)
Abstract
Se refiere a nuevos derivados de catecolamina de la formula 1, a procesos para su preparacion, a composiciones farmacéuticas que los contienen y a su uso en terapia, en enfermedades neurodegenerativas. Reivindicacion 1: Un compuesto que tiene la estructura (1) en donde n = 0, 1; R1 y R2 están independientemente seleccionados de hidrogeno, alcanoilo C1-6, fenilacetilo o benzoilo, R3 está seleccionado del grupo integrado por hidrogeno, metilo, etilo, n-propilo, ciclo-propilo, ciclo-butilo, alilo, propargilo, hidroxietilo, 3-fluorpropilo y 2-fluoretilo, y sales de adicion de ácidos farmacéuticamente aceptables del mismo, siempre que el compuesto no sea uno de los siguientes racematos: 1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol racémico, 1-metil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol racémico, 1-etil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol racémico, 1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol racémico
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200701250 | 2007-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068045A1 true AR068045A1 (es) | 2009-10-28 |
Family
ID=39877715
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103713A AR068044A1 (es) | 2007-08-31 | 2008-08-27 | Derivados de catecolamina y prodrogas de los mismos |
| ARP080103714A AR068045A1 (es) | 2007-08-31 | 2008-08-27 | Derivados de catecolamina y prodrogas de los mismos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103713A AR068044A1 (es) | 2007-08-31 | 2008-08-27 | Derivados de catecolamina y prodrogas de los mismos |
Country Status (29)
| Country | Link |
|---|---|
| EP (4) | EP2662358A1 (es) |
| JP (4) | JP2010536890A (es) |
| KR (3) | KR20100051834A (es) |
| CN (3) | CN101842354A (es) |
| AR (2) | AR068044A1 (es) |
| AU (2) | AU2008291425B2 (es) |
| BR (2) | BRPI0813456A2 (es) |
| CA (2) | CA2691961C (es) |
| CL (2) | CL2008002558A1 (es) |
| CO (2) | CO6270232A2 (es) |
| CY (1) | CY1117326T1 (es) |
| DK (1) | DK2197883T3 (es) |
| EA (2) | EA018011B1 (es) |
| ES (1) | ES2557485T3 (es) |
| HR (1) | HRP20151334T1 (es) |
| HU (1) | HUE025882T2 (es) |
| IL (1) | IL203080A (es) |
| MX (1) | MX2010002210A (es) |
| MY (2) | MY148948A (es) |
| NZ (2) | NZ583551A (es) |
| PL (1) | PL2197883T3 (es) |
| PT (1) | PT2197883E (es) |
| RS (1) | RS54470B1 (es) |
| SG (1) | SG184711A1 (es) |
| SI (1) | SI2197883T1 (es) |
| TW (2) | TWI404702B (es) |
| UA (2) | UA97989C2 (es) |
| WO (2) | WO2009026934A1 (es) |
| ZA (2) | ZA200909191B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI404702B (zh) * | 2007-08-31 | 2013-08-11 | Lundbeck & Co As H | 兒茶酚胺衍生物和其前藥 |
| US8067410B2 (en) | 2008-06-27 | 2011-11-29 | H. Lundbeck A/S | Phenolic and catecholic amines and prodrugs thereof |
| EP2303851A1 (en) * | 2008-06-27 | 2011-04-06 | H. Lundbeck A/S | Novel phenolic and catecholic amines and prodrugs thereof |
| TW201035054A (en) * | 2009-02-27 | 2010-10-01 | Lundbeck & Co As H | Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof |
| TW201036949A (en) * | 2009-02-27 | 2010-10-16 | Lundbeck & Co As H | Treatment of dyskinesia related disorders |
| TWI816716B (zh) | 2017-11-24 | 2023-10-01 | 丹麥商Ｈ 朗德貝克公司 | 用於治療帕金森病之新兒茶酚胺前驅藥 |
| WO2020070099A1 (en) | 2018-10-02 | 2020-04-09 | H. Lundbeck A/S | Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11168056B2 (en) * | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| JP7514859B2 (ja) * | 2019-05-21 | 2024-07-11 | ハー・ルンドベック・アクチエゼルスカベット | パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ |
| JP7696829B2 (ja) * | 2019-05-21 | 2025-06-23 | ハー・ルンドベック・アクチエゼルスカベット | パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ |
| US12391650B2 (en) | 2019-05-21 | 2025-08-19 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's disease |
| EP3972970A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| CN114478298B (zh) * | 2020-11-12 | 2024-09-27 | 成都西岭源药业有限公司 | 一种造影剂碘佛醇的纯化方法 |
| JP2023552699A (ja) | 2020-11-17 | 2023-12-19 | ハー・ルンドベック・アクチエゼルスカベット | パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ |
| CN113620760A (zh) * | 2021-09-07 | 2021-11-09 | 张家口思睿凯科技有限公司 | 一种电子盐反应液和不饱和芳香烃类化合物的还原方法 |
| WO2025078574A1 (en) * | 2023-10-12 | 2025-04-17 | Integrative Research Laboratories Sweden Ab | NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080456A (en) * | 1971-10-26 | 1978-03-21 | Schering Aktiengesellschaft | Diacylapomorphines |
| CH648300A5 (en) * | 1979-06-22 | 1985-03-15 | Sandoz Ag | Phenanthrene derivatives and medicaments containing them |
| US4543256A (en) * | 1982-03-17 | 1985-09-24 | Northeastern University | (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers |
| WO1990012574A1 (en) * | 1989-04-25 | 1990-11-01 | Northeastern University | Dopamine agonist compounds |
| DD299303A5 (de) * | 1989-08-30 | 1992-04-09 | ��@���������@�������k�� | Indolobenzoquinolinderivate, deren herstellung und verwendung als antiarrhythmische medikamente |
| TW357143B (en) * | 1995-07-07 | 1999-05-01 | Novartis Ag | Benzo[g]quinoline derivatives |
| JPH11515030A (ja) * | 1995-11-10 | 1999-12-21 | ノボ ノルディスク アクティーゼルスカブ | シス−ベンズ［ｅ］インドール化合物のエナンチオマー、これらの製造、及びドーパミン−Ｄ３受容体選択的医薬としての利用 |
| CN1241998A (zh) * | 1996-10-30 | 2000-01-19 | 伊莱利利公司 | 苯并[f]喹啉酮的合成 |
| SE0002934D0 (sv) * | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
| SE0102036D0 (sv) | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
| AR030357A1 (es) * | 2000-08-18 | 2003-08-20 | Lundbeck & Co As H | Derivados 4 -, 5 -, 6 - y 7-indol |
| US20050090518A1 (en) * | 2003-10-24 | 2005-04-28 | Nastech Pharmaceutical Company Inc. | Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
| TWI404702B (zh) * | 2007-08-31 | 2013-08-11 | Lundbeck & Co As H | 兒茶酚胺衍生物和其前藥 |
-
2008
- 2008-08-19 TW TW097131506A patent/TWI404702B/zh not_active IP Right Cessation
- 2008-08-27 AR ARP080103713A patent/AR068044A1/es active IP Right Grant
- 2008-08-27 AR ARP080103714A patent/AR068045A1/es not_active Application Discontinuation
- 2008-08-28 MY MYPI2010000841A patent/MY148948A/en unknown
- 2008-08-28 HR HRP20151334TT patent/HRP20151334T1/hr unknown
- 2008-08-28 JP JP2010522187A patent/JP2010536890A/ja active Pending
- 2008-08-28 KR KR1020107004461A patent/KR20100051834A/ko not_active Ceased
- 2008-08-28 EP EP13175011.9A patent/EP2662358A1/en not_active Withdrawn
- 2008-08-28 CN CN200880113440A patent/CN101842354A/zh active Pending
- 2008-08-28 SI SI200831554T patent/SI2197883T1/sl unknown
- 2008-08-28 SG SG2012064408A patent/SG184711A1/en unknown
- 2008-08-28 MX MX2010002210A patent/MX2010002210A/es active IP Right Grant
- 2008-08-28 HU HUE08784472A patent/HUE025882T2/en unknown
- 2008-08-28 JP JP2010522186A patent/JP5548125B2/ja not_active Expired - Fee Related
- 2008-08-28 NZ NZ583551A patent/NZ583551A/en not_active IP Right Cessation
- 2008-08-28 PT PT87844726T patent/PT2197883E/pt unknown
- 2008-08-28 KR KR1020097027342A patent/KR101597367B1/ko not_active Expired - Fee Related
- 2008-08-28 PL PL08784472T patent/PL2197883T3/pl unknown
- 2008-08-28 WO PCT/DK2008/050214 patent/WO2009026934A1/en active Application Filing
- 2008-08-28 KR KR1020157026863A patent/KR20150115963A/ko not_active Ceased
- 2008-08-28 ES ES08784472.6T patent/ES2557485T3/es active Active
- 2008-08-28 EP EP08784472.6A patent/EP2197883B1/en active Active
- 2008-08-28 CA CA2691961A patent/CA2691961C/en active Active
- 2008-08-28 WO PCT/DK2008/050215 patent/WO2009026935A1/en active Application Filing
- 2008-08-28 AU AU2008291425A patent/AU2008291425B2/en not_active Ceased
- 2008-08-28 EP EP08784473A patent/EP2195291A1/en not_active Withdrawn
- 2008-08-28 EP EP15188376.6A patent/EP3009437A1/en not_active Withdrawn
- 2008-08-28 EA EA200971107A patent/EA018011B1/ru not_active IP Right Cessation
- 2008-08-28 EA EA201070327A patent/EA018413B1/ru not_active IP Right Cessation
- 2008-08-28 CN CN200880023124A patent/CN101687878A/zh active Pending
- 2008-08-28 RS RS20150874A patent/RS54470B1/en unknown
- 2008-08-28 BR BRPI0813456-1A2A patent/BRPI0813456A2/pt not_active Application Discontinuation
- 2008-08-28 CN CN201710269745.1A patent/CN107253956A/zh active Pending
- 2008-08-28 MY MYPI20095490A patent/MY179527A/en unknown
- 2008-08-28 BR BRPI0815894-0A2A patent/BRPI0815894A2/pt not_active IP Right Cessation
- 2008-08-28 CA CA2697688A patent/CA2697688A1/en not_active Abandoned
- 2008-08-28 UA UAA201000849A patent/UA97989C2/uk unknown
- 2008-08-28 DK DK08784472.6T patent/DK2197883T3/en active
- 2008-08-28 NZ NZ582379A patent/NZ582379A/en not_active IP Right Cessation
- 2008-08-28 AU AU2008291426A patent/AU2008291426B2/en not_active Ceased
- 2008-08-28 UA UAA201003349A patent/UA98804C2/ru unknown
- 2008-08-29 CL CL2008002558A patent/CL2008002558A1/es unknown
- 2008-08-29 CL CL2008002564A patent/CL2008002564A1/es unknown
- 2008-08-29 TW TW097133076A patent/TW200914426A/zh unknown
-
2009
- 2009-12-23 ZA ZA2009/09191A patent/ZA200909191B/en unknown
- 2009-12-30 CO CO09149335A patent/CO6270232A2/es active IP Right Grant
- 2009-12-31 IL IL203080A patent/IL203080A/en active IP Right Grant
-
2010
- 2010-02-26 ZA ZA2010/01422A patent/ZA201001422B/en unknown
- 2010-02-26 CO CO10023455A patent/CO6260082A2/es active IP Right Grant
-
2014
- 2014-02-06 JP JP2014021193A patent/JP2014111635A/ja active Pending
- 2014-04-17 JP JP2014085192A patent/JP5802792B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-28 CY CY20151101191T patent/CY1117326T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068045A1 (es) | Derivados de catecolamina y prodrogas de los mismos | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| AR055060A1 (es) | Derivados de n-(piridin-2-il)-sulfonamida | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| UY32483A (es) | Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
| AR066130A1 (es) | Formas cristalinas de saxagliptina y procesos para preparar las mismas | |
| ECSP088774A (es) | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricación. | |
| PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| UY30107A1 (es) | Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| DOP2012000310A (es) | Morfolinopirimidinas y su uso en terapia | |
| NI201800051A (es) | Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer | |
| CO6290658A2 (es) | Derivados de azetidina y ciclobutano como inhibidores de jack | |
| UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| CL2012001056A1 (es) | Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras. | |
| AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
| UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| ECSP077402A (es) | Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica | |
| AR060914A1 (es) | Derivados de furopiridina como ligandos receptores de la acetilcolina nicotinica, una composicion farmaceutica que los comprende y su empleo en la manufactura de un medicamento para el tratamiento de una enfermedad mediada por la activacion del receptor alfa7-nicotinico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |